Breaking Canadian GLP-1 news
GLP-1 News — Page 2
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
BMJ: Canada Second Country Globally to Approve Generic Semaglutide
BMJ reports Canada is only the second country worldwide to approve generic semaglutide, following Health Canada nods to Dr. Reddy's and Apotex.
The $250 Fee: How a Lapsed Patent Opened Canada's Generic Market
Novo Nordisk stopped paying a $C250 annual patent maintenance fee in 2018, a decision that ultimately let generic semaglutide reach Canadian pharmacies in 2026.
Novo Nordisk Forecasts 2026 Sales Drop as Lilly Projects $83B
Novo Nordisk projects a 5-13% 2026 sales decline while Eli Lilly forecasts $80-83B, as generic semaglutide reaches Canadian pharmacies.
pCPA Tiered Pricing: How Generic Semaglutide Prices Will Fall
Canada's pCPA pricing tiers set generic semaglutide at 75-85% of brand for the first entrant, dropping to 35% once three or more generics reach the market.
Rexall Launches Home Delivery of Ozempic, Wegovy, Rybelsus
Rexall and Novo Nordisk Canada launch Novo Nordisk Care Rx home delivery for Ozempic, Wegovy and Rybelsus across all provinces and territories except Quebec.
Novo Nordisk Ozempic Savings Card Targets Uninsured Canadians
Novo Nordisk Canada launches a savings card for Ozempic aligning brand pricing with generics for uninsured Canadians, excluding Quebec, via Rexall pharmacies.
Novo Nordisk Guides 5-13% Revenue Drop as Canada Generics Bite
Novo Nordisk forecasts a 5-13% revenue decline in 2026 as Canadian generic semaglutide reaches pharmacies and the company rolls out a savings card outside Quebec.
Doustdar Calls Wegovy Pill a 'Must-Win' as Canada Generics Land
Novo Nordisk CEO Mike Doustdar frames the oral Wegovy launch as a must-win 2026 battle as Canadian generic semaglutide from Dr. Reddy's and Apotex ships.
Health Canada Backlog Tops 500 Files as Semaglutide Queue Sits at 7
The CGPA says over 500 generic submissions sit at Health Canada with 100+ backlogged, while seven generic semaglutide files still await decisions.
Novo Nordisk's Oral Wegovy Approved in U.S. as 2026 Fight Begins
Novo Nordisk secured U.S. approval for an oral Wegovy pill in December 2025, setting up a 2026 competitive battle with Eli Lilly's orforglipron.
Plan Sponsors Brace for Canada's 65% Semaglutide Price Trigger
Canadian benefits plans face a 65% list-price cut once a third generic semaglutide launches, with Sandoz now targeting Q3 2026 and Aspen going Canada-first.
Sandoz Estimates $200-$400 Generic Tirzepatide as Canada Warns on Fakes
Sandoz estimates its proposed generic tirzepatide at $200-$400 monthly as Health Canada renews warnings about unauthorized GLP-1 products sold outside licensed pharmacies.
Sandoz Files U.S. Generic Tirzepatide Bids as Lilly Raises Canada Prices
Sandoz's U.S. FDA generic tirzepatide filings land as Eli Lilly raises Mounjaro KwikPen prices in Canada under Trump administration pressure.
Health Canada Registry: Aspen-Semaglutide and Sevmia Approved, Neither Marketed
Health Canada's Drug Product Database lists Aspen-Semaglutide and Sevmia as Approved with no market date as of July 28, 2026. Why neither can be bought yet.
Novo Nordisk Let Canadian Ozempic Patent Extension Lapse: I-MAK
Novo Nordisk could have extended its Canadian Ozempic patent until 2028 but did not renew it, patent expert Tahir Amin of I-MAK told the BBC.
Health Canada Registry: Six Generic Semaglutide Files Pending
Health Canada's public submissions registry shows six generic semaglutide applications still under review after the June 29, 2026 Sevmia authorization.
TrumpRx US GLP-1 Deal: Limited Spillover for Canadian Prices
US TrumpRx program starts GLP-1 prices at US$350 dropping to US$245, but Canadian prices are already lower and generic semaglutide is reshaping the market.
Vimy Pharma Eyes Edmonton-Made Generic Semaglutide Launch
Toronto-based Vimy Pharma plans to file generic semaglutide with Health Canada, with production slated for an Edmonton facility employing about 30 people.
Apotex CEO Says US Launch of Generic Semaglutide Not in 2026
Apotex CEO Martin Arès told the BBC the company's generic semaglutide will not reach the US market in 2026 despite tentative FDA approval.
Sandoz Files US Generic Tirzepatide Applications; Canada Watches
Sandoz files two US generic tirzepatide applications with the FDA, estimating $200-$400 monthly pricing, as Canadian tirzepatide patents differ from US 2036 protection.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada